Condition: Non-small Cell Lung Cancer · Anaplastic Lymphoma Kinase-positive · Sponsor: Nuvalent Inc.
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
This description comes directly from the study's public registry record.
Nuvalent Clinical Trials · 857-357-7000 · clinicaltrials@nuvalent.com
Always discuss trial participation with your own doctor first.
| Palo Verde Hematology Oncology | Glendale, Arizona, United States | Recruiting |
| Hoag Hospital Newport Beach | Newport Beach, California, United States | Recruiting |
| University of California, Irvine Health | Orange, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Boulder, Colorado, United States | Recruiting |
| Sylvester Comprehensive Cancer Center Miami | Miami, Florida, United States | Recruiting |
| AdventHealth Cancer Institute | Orlando, Florida, United States | Recruiting |
| H Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | Recruiting |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | Withdrawn |
| Washington University Center for Advanced Medicine | St Louis, Missouri, United States | Recruiting |
| NYU Langone's Perlmutter Cancer Center | New York, New York, United States | Recruiting |
+ 145 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06765109